Vivos Pocfratio from 2010 to 2024

VVOS Stock  USD 3.20  0.25  8.47%   
Vivos Therapeutics POCF Ratio yearly trend continues to be comparatively stable with very little volatility. POCF Ratio will likely drop to -1.33 in 2024. From the period from 2010 to 2024, Vivos Therapeutics POCF Ratio quarterly data regression had mean square error of  30.79 and mean deviation of  7.07. View All Fundamentals
 
POCF Ratio  
First Reported
2010-12-31
Previous Quarter
(1.27)
Current Value
(1.33)
Quarterly Volatility
8.29987228
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vivos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vivos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 141.3 K, as well as many indicators such as Price To Sales Ratio of 1.04, Dividend Yield of 0.0 or PTB Ratio of 38.75. Vivos financial statements analysis is a perfect complement when working with Vivos Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Vivos Therapeutics Correlation against competitors.
For more information on how to buy Vivos Stock please use our How to Invest in Vivos Therapeutics guide.

Latest Vivos Therapeutics' Pocfratio Growth Pattern

Below is the plot of the Pocfratio of Vivos Therapeutics over the last few years. It is Vivos Therapeutics' POCF Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vivos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Pocfratio10 Years Trend
Slightly volatile
   Pocfratio   
       Timeline  

Vivos Pocfratio Regression Statistics

Arithmetic Mean(14.79)
Coefficient Of Variation(56.14)
Mean Deviation7.07
Median(19.54)
Standard Deviation8.30
Sample Variance68.89
Range20.4195
R-Value0.76
Mean Square Error30.79
R-Squared0.58
Significance0.0009
Slope1.42
Total Sum of Squares964.43

Vivos Pocfratio History

2024 -1.33
2023 -1.27
2022 -0.47
2021 -3.04
2020 -18.95
2019 -20.89

About Vivos Therapeutics Financial Statements

Vivos Therapeutics shareholders use historical fundamental indicators, such as Pocfratio, to determine how well the company is positioned to perform in the future. Although Vivos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Vivos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Vivos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
POCF Ratio(1.27)(1.33)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vivos Stock Analysis

When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.